ONTARGET programme of cardio- and vascular protection - first results are imminent.
D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage*; D001565:Benzoates / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000503:physiopathology; D002454:Cell Differentiation / Q000187:drug effects; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D022781:Hepatocytes / Q000166:cytology / Q000187:drug effects; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects; D008297:Male; D017257:Ramipril / Q000008:administration & dosage*; D020521:Stroke / Q000188:drug therapy* / Q000503:physiopathology; D000077333:Telmisartan; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001565:Benzoates; D017257:Ramipril; D000077333:Telmisartan